TELAHealthcare · Medical DevicesThe 6 Wall Street analysts covering TELA Bio, Inc. hold a median 12-month price target of $2 — +90.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores TELA Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on TELA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +90.5% from it.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Sept 2026 | Craig-Hallum | Initiates | Buy | $2.00 |
| 27 Mar 2026 | Citizens | Maintains | Market Outperform | — |
| 27 Mar 2026 | Citizens | Maintains | Market Outperform | $5.00 → $3.00 |
| 25 Mar 2026 | Canaccord Genuity | Maintains | Buy | $4.00 → $2.00 |
| 25 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 25 Mar 2026 | Lake Street | Maintains | Buy | — |
| 25 Mar 2026 | Lake Street | Maintains | Buy | $3.00 → $2.00 |
| 25 Mar 2026 | Piper Sandler | Maintains | Neutral | — |
| 25 Mar 2026 | Piper Sandler | Maintains | Neutral | $1.25 → $1.00 |
| 1 Dec 2025 | Lake Street | Maintains | Buy | — |
| 18 Nov 2025 | Canaccord Genuity | Maintains | Buy | — |
| 14 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 14 Nov 2025 | Piper Sandler | Reiterates | Neutral | — |
| 21 Mar 2025 | Canaccord Genuity | Maintains | Buy | — |
| 21 Mar 2025 | Citizens Capital Markets | Maintains | Market Outperform | — |
| 21 Mar 2025 | Piper Sandler | Downgrade | Neutral | — |
| 8 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 4 Oct 2024 | Canaccord Genuity | Maintains | Buy | — |
| 13 Aug 2024 | Canaccord Genuity | Maintains | Buy | — |
| 13 Aug 2024 | JMP Securities | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TELA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, TELA Bio, Inc. returned −31.4% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 78% of US stocks
Cheaper than 96% of US stocks
Cheaper than 74% of US stocks
Higher than 20% of US stocks
Higher than 31% of US stocks
Higher than 85% of US stocks
Higher than 17% of US stocks
Higher than 10% of US stocks
Higher than 3% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
TELA Bio, Inc. has a market value of $49.2M and an enterprise value of $76.4M.
Revenue in the twelve months to 30 June 2026: $79.9M. The latest quarter shrank 4.5% year on year.
Net income over the same four quarters: −$41.2M, a −51.5% net margin.
Diluted earnings per share, trailing twelve months: $−0.77.
Free cash flow in the twelve months to 30 June 2026: −$31.6M.
Trailing P/E: −1.3×; forward P/E: −2.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
TELA Bio, Inc. employs 218 people — $367K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own TELA Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of a TELA Bio, Inc. shareholder/analyst call; no further call details are provided in the excerpt.
Why it matters — The transcript may provide TELA watchers with information from a shareholder/analyst call, but the excerpt does not specify its topics or conclusions.
TELA Bio announced that the U.S. Food and Drug Administration granted 510(k) clearance for its Liora Monofilament Scaffold, a product intended for soft tissue reinforcement. The clearance was announced on October 5, 2026 by the company, a commercial-stage medical technology firm focused on soft-tissue reconstruction.
Why it matters — A TELA watcher would care because adding a newly FDA-cleared product to its soft-tissue reconstruction portfolio could broaden the company's commercial offerings in that market.
TELA Bio announced a transition in its Chief Operating Officer and Chief Financial Officer roles alongside a strategic cost reduction initiative. As part of the efficiency program, the company plans to reduce annual operating expenses by $17.0 million, or 18%.
Why it matters — TELA watchers would care because the leadership transition and 18% operating expense reduction signal a significant operational restructuring that could affect the company's financial trajectory.
TELA Bio, Inc. released its Q2 2026 earnings call transcript, published via Seeking Alpha. The transcript covers the company's second-quarter financial results and management discussion.
Why it matters — A TELA watcher would review this transcript for management commentary and financial detail on the company's Q2 2026 performance.
TELA Bio reported a second-quarter loss of $0.20 per share, wider than the Zacks Consensus Estimate of a $0.17 loss, and lagged revenue estimates. The result compares with a $0.22 per share loss in the same period a year ago.
Why it matters — The results came in below analyst expectations for both earnings and revenue, providing an update on the company's recent financial performance for TELA watchers.
The 6 Wall Street analysts covering TELA Bio, Inc. have a median 12-month price target of $2, with estimates ranging from $1 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering TELA Bio, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TELA Bio, Inc. 34 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, TELA Bio, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +90.5% from the last close, and Ticker Nerd's factor model ranks TELA Bio, Inc. 34 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering TELA Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TELA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $3 over the next 12 months.
TELA Bio, Inc. returned -31.4% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions for surgeons and healthcare providers.
The most recent item we track (Seeking Alpha, 8 Oct 2026): "TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript". Seeking Alpha published a transcript of a TELA Bio, Inc. shareholder/analyst call; no further call details are provided in the excerpt.
TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions for surgeons and healthcare providers. The company develops and markets reinforced tissue matrix products designed for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery, with an emphasis on preserving and restoring the patient’s own anatomy. Its OviTex portfolio includes products for open, laparoscopic, and robotic procedures, as well as configurations tailored to different surgical needs in general surgery and reconstructive care. TELA Bio also supports applications that aim to reduce reliance on permanent synthetic materials while leveraging the body’s natural healing response. Headquartered in Malvern, Pennsylvania, TELA Bio serves the medical device market through products that address unmet needs in modern soft-tissue repair.
CEO Ms. Heather C. Getz CPA, M.B.A. · 218 employees · United States · https://www.telabio.com
